Roxanne  Singer-Gheorghiu, APRN

Clinical Trials

 

REGAIN – “A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Chronic Migraine.” Sub-investigator; sponsored by Eli Lilly 2015-present. Enrolled first patient in the nation

 

“An Open-Label Study to Assess the Effects of BG00012 on Lymphocyte Subsets in Subjects With Relapsing-Remitting Multiple Sclerosis.” Sub-investigator; Sponsored by Biogen. 2015-present

 

AMARANTH – “A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic study of ‘study drug' in Early Alzheimer's Disease.” Sub-investigator; Sponsored by AstraZeneca AB. 2015-present

 

REDEFINE – “A phase IV, randomized, prospective, US-based, multicenter, cross-over study evaluating subject ease-of-use with ‘study drug' and ‘study drug' auto injectors in subjects with relapsing remitting multiple sclerosis (RRMS) treated with ‘study drug' subcutaneously three times a week .”Sub Investigator; Sponsored by EMD Serono, Inc. 2015-present

 

“An Open-Label Extension study of ‘study drug' for 52 weeks in pain associated with Fibromyalgia. “Sub-Investigator; Sponsored by Daiichi Pharma Development. 2015-present

 

“PLEGRIDY – (peginterferon?-1a) Real World Effectiveness and Safety Observational Program.” Sponsored by Biogen Idec. 2014 –present

 

ESTEEM – “A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of ‘study drug' When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis.”; Sponsored by Biogen Idec. 2013-present. Enrolled first global patient

 

ASSESS – “A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of ‘study drug' and ‘study drug' administered orally once daily with ‘study drug' administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis.” Rater; Sponsored by Novartis Pharmaceuticals. 2013-present

 

“A Triple-Blind, Randomized, Placebo-Controlled, Parallel-Group Multicenter Study to Evaluate the Efficacy and Tolerability of the Addition of Alendronate Sodium to Ongoing Hormone Replacement therapy in the Treatment of Osteoporosis in Postmenopausal Women.” Co-investigator; Sponsored by Merck 1995